Cargando…
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
BACKGROUND: There is uncertainty regarding the safety and effectiveness of direct oral anticoagulant agents in patients with antiphospholipid syndrome (APS). We performed a multicenter feasibility study to examine our ability to identify and obtain consent from eligible APS patients and to obtain 95...
Autores principales: | Legault, Kimberly, Blostein, Mark, Carrier, Marc, Khan, Susan, Schulman, Sam, Shivakumar, Sudeep, Wu, Cynthia, Crowther, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183116/ https://www.ncbi.nlm.nih.gov/pubmed/32346486 http://dx.doi.org/10.1186/s40814-020-00594-1 |
Ejemplares similares
-
Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
por: Legault, Kimberly, et al.
Publicado: (2020) -
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015) -
Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure
por: Granowicz, Eric, et al.
Publicado: (2018) -
Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
por: Carrier, Marc, et al.
Publicado: (2021) -
Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
por: Haładyj, Ewa, et al.
Publicado: (2016)